I pulled this extract from 'The Telethon Institute' 2010 annual report(published May2011). It's on page 21, under the heading:
'Discovering New Antimicrobials Against Multi-resistant Microorganisms(Collaboration with Medimmune)'.
Recent studies have explored the potential synergy between clinical antibiotics and antimicrobial Phylomer peptides and found at least one potent combination. We have found a number of peptides with antimicrobial activity against the nosocomial infective agent Pseudomonas. aeruginosa. We have established a control panel of recently published, highly active natural antimicrobial peptides and compared them with antimicrobial Phylomer peptides under different salt conditions (different broths), and have identified Phylomer derivatives which are more active than a potent antimicrobial peptide known as Tachyplesin which is isolated from the horse-shoe crab. ...............
The first part of this extract seems to be discussing combining current antibiotics and phylomer peptides (the re-engineering of current antibiotics is discussed in the Reuters article, in Peace's last post on this thread). . IMO the extract shows, PYC will be supplying the goods as requested for the Medimmune collaboration.
The link to the Telethon Institute report is below. Page 20 & 21 concern PYC work.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)